Clinical trial
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+…
NCT00392392 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00392392 |
|---|---|
| Title | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer |
| Official title | Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered With ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Celgene Corporation Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | nab-paclitaxel, Bevacizumab, Trastuzumab |
| Enrollment | 29 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Dec 1, 2011 |
| First posted | Oct 26, 2006 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: